Lv11
40 积分 2026-01-29 加入
Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis
14小时前
已完结
The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency
4天前
已完结
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
13天前
已关闭
Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics
14天前
已完结
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell Lymphoma
19天前
已完结
MYC-Mediated Synthetic Lethality for Treating Tumors
19天前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
20天前
已完结
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients
24天前
已完结
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
25天前
已完结
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
26天前
已完结
皖公网安备34019202002308
